During the last session, LENZ Therapeutics Inc (NASDAQ:LENZ)’s traded shares were 0.49 million, with the beta value of the company hitting 0.51. At the end of the trading day, the stock’s price was $34.69, reflecting an intraday gain of 1.26% or $0.43. The 52-week high for the LENZ share is $38.93, that puts it down -12.22 from that peak though still a striking 52.35% gain since the share price plummeted to a 52-week low of $16.53. The company’s market capitalization is $976.39M, and the average intraday trading volume over the past 10 days was 0.38 million shares, and the average trade volume was 270.99K shares over the past three months.
LENZ Therapeutics Inc (LENZ) received a consensus recommendation of Buy from analysts. That translates to a mean rating of 1.12. LENZ has a Sell rating from 0 analyst(s) out of 2 analysts who have looked at this stock. 0 analyst(s) recommend to Hold the stock while 0 suggest Overweight, and 2 recommend a Buy rating for it.
LENZ Therapeutics Inc (NASDAQ:LENZ) trade information
LENZ Therapeutics Inc (LENZ) registered a 1.26% upside in the last session and has traded in the green over the past 5 sessions. The stock spiked 1.26% in intraday trading to $34.69, hitting a weekly high. The stock’s 5-day price performance is 6.64%, and it has moved by 23.54% in 30 days. Based on these gigs, the overall price performance for the year is 20.16%. The short interest in LENZ Therapeutics Inc (NASDAQ:LENZ) is 3.4 million shares and it means that shorts have 15.08 day(s) to cover.
The consensus price target of analysts on Wall Street is $51, which implies an increase of 31.98% to the stock’s current value. The extremes of the forecast give a target low and a target high price of $51 and $51 respectively. As a result, LENZ is trading at a discount of -47.02% off the target high and -47.02% off the low.
An analysis of the company’s performance over the past 5 years shows that the company’s earnings shrunk an estimated -181.63%. While earnings are projected to return -21.02% in 2025, the next five years will return 31.56% per annum.
LENZ Dividends
LENZ Therapeutics Inc is due to release its next quarterly earnings on 2025-May-07. However, it is important to remember that the dividend yield ratio is merely an indicator meant to only serve as guidance.
LENZ Therapeutics Inc (NASDAQ:LENZ)’s Major holders
LENZ Therapeutics Inc insiders own 2.76% of total outstanding shares while institutional holders control 94.17%, with the float percentage being 96.84%. RA CAPITAL MANAGEMENT, L.P. is the largest shareholder of the company, while 163.0 institutions own stock in it. As of 2024-06-30, the company held over 4.18 million shares (or 16.318% of all shares), a total value of $72.25 million in shares.
The next largest institutional holding, with 3.61 million shares, is of ALPHA WAVE GLOBAL, LP’s that is approximately 14.1055% of outstanding shares. At the market price on 2024-06-30, these shares were valued at $62.46 million.
Also, the Mutual Funds coming in first place with the largest holdings of LENZ Therapeutics Inc (LENZ) shares are VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF . Data provided on Mar 31, 2025 indicates that VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund owns about 811.48 shares. This amounts to just over 2.88 percent of the company’s overall shares, with a $28.15 million market value. The same data shows that the other fund manager holds slightly less at 320.31, or about 1.14% of the stock, which is worth about $11.11 million.
